Search

Your search keyword '"Diaz-Rohena R"' showing total 2 results
Start Over Author "Diaz-Rohena R" Publication Year Range Last 10 years
2 results on '"Diaz-Rohena R"'

1. The effects of temporary intraocular pressure spikes after intravitreal dexamethasone implantation on the retinal nerve fiber layer

Author

Wannamaker KW, Kenny S, Das R, Mendlovitz A, Comstock JM, Chu ER, Bahadorani S, Gresores NJ, Beck KD, Krambeer CJ, Kermany DS, Diaz-Rohena R, Nolan DP, Sohn JH, and Singer MA

Subjects
Ozurdex, dexamethasone, glaucoma, intraocular pressure, retinal nerve fiber layer, ocular hypertension., Ophthalmology, RE1-994
Abstract

Kendall W Wannamaker,1 Sarah Kenny,1 Rishi Das,1 Aaron Mendlovitz,2 Jordan M Comstock,1 Edward R Chu,1 Sepehr Bahadorani,1 Nathan J Gresores,2 Kinley D Beck,1 Chelsey J Krambeer,2 Daniel S Kermany,2 Roberto Diaz-Rohena,1 Daniel P Nolan,2 Jeong-Hyeon Sohn,1 Michael A Singer21Ophthalmology, University of Texas Health Science Center San Antonio, San Antonio, TX, USA; 2Medical Center Ophthalmology Associates, San Antonio, TX, USABackground and objective: The dexamethasone (DEX) implant is known to cause temporary intraocular pressure (IOP) spikes after implantation. The purpose of this study is to determine if IOP spikes after DEX implant cause significant thinning in the retinal nerve fiber layer (RNFL).Study design, patients, and methods: A total of 306 charts were reviewed with 48 and 21 patients meeting inclusion criteria for the cross-sectional and prospective groups, respectively. Cross-sectional inclusion criteria: IOP spike ≥22 mmHg up to 16 weeks after DEX implant, DEX implant in only 1 eye per patient, and spectral-domain optical coherence tomography (OCT) RNFL imaging of both eyes ≥3 months after IOP spike. Prospective inclusion criteria: OCT RNFL performed within 1 year prior to DEX implantation, IOP spike ≥22 mmHg up to 16 weeks after DEX implant, and OCT RNFL performed ≥3 months after IOP spike. The average RNFL thickness in the contralateral eye was used as the control in the cross-sectional group. Institutional review board approval was obtained.Results: In the cross-sectional group, there was no statistically significant difference in the mean RNFL thicknesses in the treated vs untreated eyes (80.4±15.5 μm and 82.6±15.8 μm, respectively; P=0.33) regardless of treatment diagnosis, magnitude of IOP spike, or history of glaucoma. In the prospective group, mean RNFL thicknesses before and after IOP spikes ≥22 mmHg were similar (78.0±14.8 μm and 75.6±13.6 μm, respectively; P=0.13).Conclusion and relevance: Temporary elevation of IOP after DEX implantation when treated with topical IOP lowering drops does not appear to lead to a meaningful change in RNFL thickness.Keywords: Ozurdex®, dexamethasone, glaucoma, intraocular pressure, retinal nerve fiber layer, ocular hypertension

Published
2019

2. Treatment of central serous chorioretinopathy with topical NSAIDs

Author

Bahadorani S, Maclean K, Wannamaker K, Chu ER, Gresores N, Sohn JH, Diaz­-Rohena R, and Singer MA

Subjects
Ophthalmology, NSAIDs, Central serous chorioretinopathy, subretinal fluid, bromfenac, SRF, CSCR, RE1-994, CSR, CSC, nepafenac
Abstract

Sepehr Bahadorani,1 Kyle Maclean,1 Kendall Wannamaker,1 Edward Rickie Chu,1 Nathan Gresores,2 Jeong-Hyeon Sohn,1 Roberto Diaz-Rohena,1 Michael A Singer21Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA; 2Medical Center Ophthalmology Associates, San Antonio, TX, USAPurpose: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery.Methods: An IRB-approved retrospective review was conducted on patients that had been diagnosed with a new-onset, symptomatic case of CSCR. Patients were either observed only (13 untreated eyes) or treated with topical bromfenac or nepafenac (14 eyes) over an average of about a 4–5 week follow-up period.Results: There was no statistical significance between central macular thickness (CMT) and visual acuity of treatment and control groups at the initial presentation. However, at the follow-up visit, CMT reductions in the treatment group were significantly higher than in the control group (p

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results